comparemela.com

Latest Breaking News On - Swiss stock exchange adxn - Page 1 : comparemela.com

Addex and Perceptive Launch Neurosterix with $63 Million to

Addex receives CHF5M and 20% share of Neurosterix Perceptive Advisors leads $63M investment into Neurosterix Addex contributes portfolio of.

New yorkUnited statesMikhail kalinichevTim dyerFred calloriRobert lutjensJean philippe rocherMike sinclairAddex neurosterixSwiss exchangePerceptive life sciences fundPerceptive xontogeny venture fundJanssen pharmaceuticals incHoc announcement pursuantPerceptive advisorsAcorn bioventures

Addex Therapeutics to Release Third Quarter 2023 Financial

Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric.

United statesTim dyerMike sinclairMikhail kalinichevSwiss exchangeThird quarterTranslational scienceAddex therapeuticsRelease third quarterProvides corporate updateConference callParticipant dial inAmerican depositary sharesExecutive officerHalsin partnersSwiss stock exchange adxn

Addex Announces Participation in the H C Wainwright 25th

Geneva, Switzerland, September 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric.

United statesNew yorkTim dyerMike sinclairSwiss exchangeChief executive officerAnnual global investment conferenceAddex therapeuticsAmerican depositary sharesExecutive officerHalsin partnersSwiss stock exchange adxnAddex therapeutics

Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout

Cohort 1 is completed, and Cohort 2 is 80% recruited Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 5, 2023 - Addex.

United statesMike sinclairTim dyerSwiss exchangeJanssen pharmaceutical companies of johnsonJanssen pharmaceuticals incHoc announcement pursuantJanssen pharmaceuticalsJanssen pharmaceutical companiesInterim review committeeAddex therapeuticsAmerican depositary sharesExecutive officerHalsin partnersSwiss stock exchange adxnAddex therapeutics

Addex Receives Nasdaq Notification Regarding Minimum Bid

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 18, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage.

United statesMike sinclairTim dyerSwiss exchangeJanssen pharmaceuticals incCompany american depositary shares adssAddex therapeuticsAmerican depositary sharesNasdaq listing ruleNasdaq listingJanssen pharmaceuticalsSwiss stock exchange adxnAddex therapeutics

vimarsana © 2020. All Rights Reserved.